Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Verastem dropped nearly 10% on October 13 to $7.45, giving back much of the recovery that prompted shorts to cover aggressively just days earlier, and the question now is whether the bear position rebuilds into the November 6 earnings date.
The covering wave documented in the October 12 note has not reversed course yet. Short interest remains at 19.7% of free float, down sharply from the 24.8% recorded a week ago, as bears who built through September used the price spike to $8.38 as an exit. Tuesday's selloff came without any meaningful re-engagement from that side: shares short barely moved on the day, down less than 0.1%. The borrow market remains uninviting for new short conviction. Availability runs at 300% of short interest, three shares available for every two already lent, making the lending pool the loosest it has been for weeks. Cost to borrow has also retreated, falling to 0.37% from 0.54% a week ago. The ORTEX short score has eased to 64.5 from highs above 67 earlier in the month, reflecting the smaller bear position even as the price has given back ground.
Options tell a different story. The put/call ratio has moved to its most defensive reading in weeks, at 0.22, which sits more than two standard deviations above its 20-day mean of 0.20. That is a small absolute number, confirming calls still dominate, but the directional shift is notable: traders added hedges into Tuesday's drop rather than buying the dip in calls. The put/call has climbed steadily from around 0.19 in mid-September to its current level, a quiet but consistent drift toward caution as the November earnings date approaches.
The Street itself is uniformly bullish, which creates one of the more visible tensions in this note. BTIG and HC Wainwright both reiterated Buy ratings with $18 targets in the past week, and Wolfe Research initiated with an Outperform in September. The consensus mean target stands at $15, more than double Tuesday's close of $7.45. Bulls rest their case on the durability of the avutometinib and defactinib combination in low-grade serous ovarian cancer, citing 30% of patients remaining on therapy beyond one year and a weighted median progression-free survival of 22.1 months in KRAS-mutant disease versus 6.5 months. The pipeline extension through VS-7375, where four registrational trials are running, provides the longer-dated option value. Bears counter that the valuation framework relies on FY37 GAAP EPS of $4.31, which is a long runway for a company whose current multiples are deeply negative, and that dilution risk from future financing rounds remains material. The analyst recommendation factor ranks in the 92nd percentile, a reflection of how unanimous the bullish stance has become, while the short score rank at the 18th percentile and the EPS surprise rank at the 34th percentile capture the credibility gap the company still has to close.
BlackRock reported a significant position build to 10.2% of shares in its September 30 filing, adding nearly 3 million shares in the quarter. State Street also added 1.6 million shares in the same period. That institutional accumulation at the index-fund level provides a technical ownership floor, but the health-care specialist holders tell a more cautious tale. Several names that had crossed the 5% threshold, including BVF Partners, OrbiMed, and Nantahala, filed amendments showing reduced stakes through mid-2025. The 13D/G register carries no activist, and stakes are as last disclosed around the 5% threshold, so holders who fell below that level may not file again.
Insider activity is all 10b5-1 plan sales, which limits the signal. The CEO and CFO both sold on October 1 under pre-arranged programmes, and the 90-day net across all insiders is negative at roughly $381,000 in value. Planned sales are compensation mechanics rather than conviction calls, but there are no offsetting open-market purchases on the register to balance the picture.
The last two earnings prints both produced one-day moves of around 15% to the upside, and five-day moves of 11% to 14%, making November 6 a meaningful binary event. Whether the recovered short position of 19.7% of float becomes the fuel for another squeeze, or whether the stock continues to give back ground ahead of the print, is the central question to track over the next three weeks.
See the live data behind this article on ORTEX.
Open VSTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
